Form 4/A for CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE
Accepted 2025-07-10 00:00:00 ET · period of report 2024-09-13 · accession 0001801170-25-000170 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AI | 2025-07-10 | 2025-07-08 | CLOV | Wai Conrad | CEO, Counterpart Health | S - Sale | $3.26 | -15.2K | 1.61M | -0.9% | -$49.6K |
| A | 2025-07-10 | 2024-09-13 | CLOV | Wai Conrad | CEO, Counterpart Health | A - Grant | $0.00 | +379.9K | 1.70M | +29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-07-08 | S | D | 15,203 | $3.26 | 1,613,498 | I | — | — | (F3) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.27, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 2 | Common | Class A Common Stock | 2024-09-13 | A | A | 379,866 | $0.00 | 1,699,767 | D By Trust. | — | — | (F1) Represents restricted stock units ("RSUs"), each representing a right to a share of Class A Common Stock, earned in connection with the determination of the level of performance achievement in satisfaction of vesting conditions underlying a performance-based restricted share unit grant awarded on October 31, 2023. One-half of the number of earned restricted stock units vested and were settled on September 13, 2024, and the remaining one-half of the restricted stock units will vest on October 31, 2025, subject to the Reporting Person's continued employment on such vesting date. This Amendment is being filed to reflect the full number of RSUs that were achieved. (F2) Number reflects total directly held Class A Common Stock taking into account the amended number and subsequent transactions through July 10, 2025. (F4) Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee. |